The extremely malignant and aggressive brain tumor, glioblastoma multiforme (GBM), is infamous for defying conventional therapeutic regimens. GBM presents considerable concerns for patients and medical personnel since it is the most prevalent and lethal primary brain tumor. However, recent developments in medical science have highlighted the promise of tailored medicines as a viable approach to treating this life-threatening illness.